Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Tipo de estudio
Intervalo de año de publicación
1.
Oncogene ; 19(36): 4184-9, 2000 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-10962581

RESUMEN

Cell proliferation is controlled by cdk2 which in association with cyclin E and A regulates G1/S transition and S phase progression. cdk2 activation is dependent on its localization in the nucleus where regulatory mediators are found. We report that activation of cdk2 is associated with the formation of cdk2/MAP Kinase complexes. cdk2 associates with both inactive and activated MAP Kinase. Prevention of MAP Kinase activation by the MEK inhibitor PD98059 inhibits both activation and nuclear localization of cdk2 and S phase entry. These findings indicate that the nuclear translocation of cdk2 is associated with the formation of molecular complexes containing active MAP Kinase and is dependent on MAP Kinase activation. Oncogene (2000) 19, 4184 - 4189


Asunto(s)
Quinasas CDC2-CDC28 , Núcleo Celular/metabolismo , Quinasas Ciclina-Dependientes/metabolismo , Interleucina-2/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Ciclo Celular/fisiología , Fraccionamiento Celular , Línea Celular , Núcleo Celular/enzimología , Quinasa 2 Dependiente de la Ciclina , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Flavonoides/farmacología , Humanos , Immunoblotting , Microscopía Confocal , Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Señales de Localización Nuclear/fisiología , Fosforilación , Linfocitos T/citología , Linfocitos T/metabolismo
2.
Oncogene ; 18(23): 3511-9, 1999 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-10376529

RESUMEN

In this study, we investigated the involvement of caspases in TGFbeta-induced apoptosis in human B cells. Our results show that TGFbeta-mediated nuclear fragmentation, observed in the Epstein-Barr virus-negative Burkitt's Lymphoma cell line BL41, was abolished in the presence of the tripeptide caspase inhibitor zVAD-fmk or the specific caspase-3 inhibitor DEVD-fmk. Other apoptotic manifestations such as cell shrinkage, surface phosphatidylserine expression and chromatin condensation were strongly inhibited by zVAD-fmk but only partially by DEVD-fmk. This suggests that other caspases in addition to caspase-3 control these apoptotis-associated features. Specific activation of caspase-3 during TGFbeta-induced apoptosis was demonstrated by the DEVD-fmk-sensitive expression of the active p17 subunit of caspase-3 and by in vivo cleavage of PARP. In addition, TGFbeta treatment of BL41 promoted the expression of both dephosphorylated and truncated forms of the retinoblastoma protein. Inhibition of caspase-3 activity abolished both nuclear fragmentation and expression of the truncated retinoblastoma protein, without modifying the G1 cell cycle arrest induced by TGFbeta. Our data thus demonstrate that TGFbeta-induced apoptosis of lymphoma B lymphocytes is dependent on caspase activation and involves caspase-dependent cleavage of the retinoblastoma protein.


Asunto(s)
Apoptosis/fisiología , Linfocitos B/fisiología , Caspasas/fisiología , Proteína de Retinoblastoma/fisiología , Factor de Crecimiento Transformador beta/fisiología , Clorometilcetonas de Aminoácidos/farmacología , Apoptosis/efectos de los fármacos , Linfoma de Burkitt/patología , Linfoma de Burkitt/fisiopatología , Caspasa 2 , Caspasa 3 , Inhibidores de Caspasas , División Celular/fisiología , Inhibidores de Cisteína Proteinasa/farmacología , Fragmentación del ADN , Activación Enzimática , Humanos , Oligopéptidos/farmacología , Proteínas , Factor de Crecimiento Transformador beta/antagonistas & inhibidores , Células Tumorales Cultivadas
3.
Cell Death Differ ; 6(5): 445-53, 1999 May.
Artículo en Inglés | MEDLINE | ID: mdl-10381635

RESUMEN

Manganese ions block apoptosis of phagocytes induced by various agents. The prevention of apoptosis was attributed to the activation of manganous superoxide dismutase (Mn-SOD) and to the antioxidant function of free Mn2+ cations. However, the effect of Mn2+ on B cell apoptosis is not documented. In this study, we investigated the effects of Mn2+ on the apoptotic process in human B cells. We observed that Mn2+ but not Mg2+ or Ca2+, inhibited cell growth and induced apoptosis of activated tonsilar B cells, Epstein Barr virus (EBV)-negative Burkitt's lymphoma cell lines (BL-CL) and EBV-transformed B cell lines (EBV-BCL). In the same conditions, no apoptosis was observed in U937, a monoblastic cell line. Induction of B cell apoptosis by Mn2+ was time- and dose-dependent. The cell permeable tripeptide inhibitor of ICE family cysteine proteases, zVAD-fmk, suppressed Mn2+-induced apoptosis. Furthermore, Mn2+ triggered the activation of interleukin-1beta converting enzyme (ICE/caspase 1), followed by the activation of CPP32/Yama/Apopain/caspase-3. In addition, poly-(ADP-ribose) polymerase (PARP), a cellular substrate for CPP32 protease was degraded to generate apoptotic fragments in Mn2+-treated B cell lines. The inhibitor, zVAD-fmk suppressed Mn2+-triggered CPP32 activation and PARP cleavage and apoptosis. These results indicate that the activation of caspase family proteases is required for the apoptotic process induced by Mn2+ treatment of B cells. While the caspase-1 inhibitor YVAD was unable to block apoptosis, the caspase-3 specific inhibitor DEVD-cmk, partially inhibited Mn2+-induced CPP32 activation, PARP cleavage and apoptosis of cells. Moreover, Bcl-2 overexpression in BL-CL effectively protected cells from apoptosis and cell death induced by manganese. This is the first report showing the involvement of Mn2+ in the regulation of B lymphocyte death presumably via a caspase-dependent process with a death-protective effect of Bcl-2.


Asunto(s)
Apoptosis , Linfocitos B/metabolismo , Caspasa 1/metabolismo , Caspasas/metabolismo , Manganeso/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Clorometilcetonas de Aminoácidos/farmacología , Linfocitos B/citología , Linfocitos B/efectos de los fármacos , Caspasa 3 , Muerte Celular/efectos de los fármacos , Línea Celular , Línea Celular Transformada , Inhibidores de Cisteína Proteinasa/farmacología , Activación Enzimática , Humanos , Manganeso/farmacología , Poli(ADP-Ribosa) Polimerasas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/genética , Células Tumorales Cultivadas
4.
J Immunol ; 158(7): 3054-61, 1997 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-9120257

RESUMEN

IL-4 activates resting B cells and, in conjunction with cosignals such as anti-IgM (anti-mu) Ab or CD40 ligand, modulates progression of B cells through the cell cycle, leading to proliferation. In this study, we show that the mitogenic combination of IL-4 and anti-mu Ab triggered induction of cyclin D3 and up-regulated cyclin-dependent kinase (cdk) 6 expression, whereas such regulation was not observed in B cells activated by IL-4 or anti-mu Ab alone. Furthermore, cyclin D3 immunoprecipitated fron as associated with cdk6, and the cyclin D3/cdk6 complex was able to phosphorylate recombinant retinoblastoma protein in vitro. In addition, B cells activated with either IL-4 or 1L-13 alone expressed a higher amount of p27kip1 (p27) cdk inhibitor than nonstimulated cells. In contrast, p27 expression was decreased when cells were activated with mitogenic combinations of IL-4 and anti-mu Ab or anti-CD40 mAb. We also observed that the IL-4-mediated inhibition of the proliferation of anti-mu/IL-2- or anti-mu/phorbol 12,13-dibutyrate-activated human leukemic B cells was associated with the maintenance of large amounts of p27 in these cells. These data suggest that IL-4 controls B cell proliferation by action during at least two steps of the regulation of the cell cycle, cyclin D3/cdk6 complex regulation and p27 inhibitor expression.


Asunto(s)
Linfocitos B/inmunología , Proteínas de Ciclo Celular , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Interleucina-4/farmacología , Activación de Linfocitos , Proteínas Asociadas a Microtúbulos/biosíntesis , Proteínas Asociadas a Microtúbulos/metabolismo , Proteínas Supresoras de Tumor , Anticuerpos Antiidiotipos/farmacología , Anticuerpos Monoclonales/farmacología , Antígenos CD40/inmunología , Células Cultivadas , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Quinasas Ciclina-Dependientes/biosíntesis , Ciclinas/análisis , Humanos , Inmunoglobulina M/inmunología , Interleucina-13/farmacología , Leucemia Linfocítica Crónica de Células B , Tonsila Palatina/citología , Fosforilación , Proteína de Retinoblastoma/metabolismo , Células Tumorales Cultivadas , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/inmunología
5.
J Immunol ; 155(12): 5623-30, 1995 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-7499846

RESUMEN

We previously reported that p56lck expression is upregulated in human B lymphocytes upon mitogenic stimulation. In this report, we characterized the molecules associated with p56lck in vivo in leukemic B cells costimulated with anti-mu Ab and IL-2 for 72 h. In vitro phosphorylation after p56lck immunoprecipitation indicated that p56lck is associated in vivo with the beta chain of the IL-2 receptor and p42 MAP kinase as well as a number of other proteins. Moreover, p56lck-associated MAP kinase is tyrosine and threonine phosphorylated, suggesting that it is activated. Prevention of DNA synthesis with aphidicolin abrogated this molecular association, and furthermore, cell cycle analysis with IL-2-dependent T cells showed that in cells in G1, MAP kinase was not associated to p56lck, whereas this p56lck-MAP kinase association was observed when cells are in S phase. Thus, p56lck and MAP kinase are only associated during S phase. These data suggest that MAP kinase in association with p56lck is directly involved in the control of IL-2-mediated DNA synthesis of both B and T lymphocytes.


Asunto(s)
Linfocitos B/efectos de los fármacos , Proteínas Quinasas Dependientes de Calcio-Calmodulina/análisis , Interleucina-2/farmacología , Proteínas Tirosina Quinasas/análisis , Familia-src Quinasas/análisis , Afidicolina/farmacología , Linfocitos B/inmunología , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Humanos , Activación de Linfocitos/efectos de los fármacos , Proteína Tirosina Quinasa p56(lck) Específica de Linfocito , Proteína Quinasa 1 Activada por Mitógenos , Fosforilación , Pruebas de Precipitina , Fase S , Células Tumorales Cultivadas
6.
Oncogene ; 11(8): 1615-22, 1995 Oct 19.
Artículo en Inglés | MEDLINE | ID: mdl-7478586

RESUMEN

Transforming growth factor beta 1 (TGF beta 1) has been shown to inhibit growth stimulation in normal human B cells as well as in Epstein Barr virus (EBV)-negative Burkitt's lymphoma (BL) cell lines. The mechanisms for this potent growth inhibition are not completely defined. Here we show that a number of EBV-negative lymphoma B cell lines (BL-41, Ramos and CAPA-2), when exposed in vitro to TGF beta 1, undergo apoptosis. Maximum apoptosis was observed at 48 h following TGF beta 1 treatment, with no apparent effect on the expression of c-myc and bcl-2 proteins. Similar induction of apoptosis was observed when these lymphoma cell lines were treated with aphidicolin, a DNA synthesis inhibitor. In contrast, various preparations (14 out of 17) of normal human tonsilar B cells showed no significant apoptosis, although both TGF beta 1 and aphidicolin inhibited anti-mu/IL-4 induced DNA synthesis in all preparations. Furthermore, another TGF beta 1 sensitive EBV-negative BL cell line, CA46, exhibited no apoptosis in response to TGF beta 1 and aphidicolin, corroborating the findings in normal human B cells. Taken together, these data support the hypothesis that exposure to TGF beta 1, which results in cell cycle arrest and DNA synthesis inhibition, may not be obligatory or sufficient for the induction of apoptosis. Rather, induction of apoptosis or lack of it may be intrinsically determined by an interplay between extracellular and intracellular regulators of cellular growth.


Asunto(s)
Linfocitos B/citología , Inhibidores de Crecimiento/farmacología , Linfoma/patología , Factor de Crecimiento Transformador beta/farmacología , Afidicolina/farmacología , Apoptosis , Ciclo Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Cromatina/ultraestructura , Inhibidores Enzimáticos/farmacología , Regulación Neoplásica de la Expresión Génica/genética , Genes myc , Humanos , Inhibidores de la Síntesis del Ácido Nucleico , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2 , Proteínas Proto-Oncogénicas c-myc/metabolismo , ARN Mensajero/genética , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA